𝔖 Bobbio Scriptorium

✦ LIBER ✦

Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of B-Type Natriuretic Peptide for the Preservation of Left Ventricular Function After Anterior Myocardial Infarction

✍ Scribed by Sangaralingham, S. Jeson; Burnett, John C.; Mckie, Paul M.; Schirger, John A.; Chen, Horng H.

Book ID: 122622568
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 459 KB
Volume: 19
Category: Article
ISSN: 1532-8414
DOI: 10.1016/j.cardfail.2013.06.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and design for TIME: A phase I

Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction

✍ Jay H. Traverse; Timothy D. Henry; Douglas E. Vaughn; Stephen G. Ellis; Carl J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Rationale and design of the Transendocar

Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy

✍ Barry Trachtenberg; Darcy L. Velazquez; Adam R. Williams; Ian McNiece; Joel Fish 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 322 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)

✍ Ik-Kyung Jang; Neil J. Weissman; Michael H. Picard; Michael R. Zile; Veronica Pe 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 264 KB

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study

✍ Ik-Kyung Jang; Veronica Pettigrew; Michael H. Picard; Peter R. Kowey; Valentin D 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 219 KB

A multicentre, randomized, double-blind

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial

✍ Olivier F. Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence 📂 Article 📅 2009 🏛 Pulsus Group Inc 🌐 English ⚖ 803 KB

Rationale and design of the RIACT–study:

Rationale and design of the RIACT–study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial

✍ Lena Schiffer, Mario Schiffer, Saskia Merkel, Anke Schwarz, Michael Mengel, Chri 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 454 KB